USB
50
4
HPE
38
2
BMY
33
-2
ECL
57
3
NEE
44
3
LB
30
11
THC
53
3
UAL
76
3
ORLY
52
5
MAT
43
2
PPL
47
3
NUE
41
2
DTE
54
5
AEE
56
5
GRMN
59
6
AMP
50
3
MSFT
58
4
NWSA
75
8
AKAM
53
5
GLW
48
4
USB
50
4
HPE
38
2
BMY
33
-2
ECL
57
3
NEE
44
3
LB
30
11
THC
53
3
UAL
76
3
ORLY
52
5
MAT
43
2
PPL
47
3
NUE
41
2
DTE
54
5
AEE
56
5
GRMN
59
6
AMP
50
3
MSFT
58
4
NWSA
75
8
AKAM
53
5
GLW
48
4
Financhill
Back

Recursion Pharmaceuticals 10K Form

Sell
44

RXRX
Recursion Pharmaceuticals

Last Price:
$7.24
Seasonality Move:
-22.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RXRX News And Ratings

See the #1 stock for the next 7 days that we like better than RXRX

RXRX Financial Statistics

Sales & Book Value

Annual Sales: $43.9M
Cash Flow: $-63.8M
Price / Cash Flow: 0
Annual Sales: $1.83
Price / Book: 3.96

Profitability

EPS (TTM): -1.55000
Net Income (TTM): $-377.8M
Gross Margin: $1.3M
Return on Equity: -78.32%
Return on Assets: -56.47%

Recursion Pharmaceuticals Earnings Forecast

Key Recursion Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 4 years for RXRX is 2.94%.
  • The Selling, General & Administrative Expenses for RXRX have been equal to 252.58% of Gross Profit Margin.
  • The Research & Development expenses have been 549.79% of Revenue.
  • The Interest Expense is -0.03% of Operating Income.
  • The Net Earning history of RXRX is -747.71% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Recursion Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RXRX
Website: recursion.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 4.35
Quick Ratio: 3.95

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RXRX Technical Analysis vs Fundamental Analysis

Sell
44
Recursion Pharmaceuticals (RXRX) is a Sell

Is Recursion Pharmaceuticals a Buy or a Sell?